Anika Therapeutics (ANIK) Debt to Equity (2010 - 2022)

Anika Therapeutics (ANIK) has 7 years of Debt to Equity data on file, last reported at $0.02 in Q2 2022.

• Debt to Equity for Q2 2022 came in at $0.02, down 74.36% year-over-year; the trailing twelve-month figure through Jun 2022 was $0.02 (down 74.36% YoY), and the FY2021 annual result was $0.02, down 68.72% from the prior year.
• Debt to Equity was little changed at $0.02 in Q2 2022 per ANIK's latest filing, from $0.02 in the prior quarter.
• Over five years, Debt to Equity peaked at $0.17 in Q2 2020 and troughed at $0.01 in Q3 2021.
• A 3-year average of $0.06 and a median of $0.05 in 2020 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2021 and 2022: Debt to Equity slumped 66.07% in 2021, then sank 83.24% in 2022.
• A 3-year view of Debt to Equity shows it stood at $0.05 in 2020, then tumbled by 68.72% to $0.02 in 2021, then grew by 0.33% to $0.02 in 2022.
• Business Quant data shows ANIK's Debt to Equity at $0.02 in Q2 2022, $0.02 in Q1 2022, and $0.02 in Q4 2021.